Survival of Recombinant Monoclonal Antibodies (IgG, IgA and sIgA) Versus Naturally-Occurring Antibodies (IgG and sIgA/IgA) in an Ex Vivo Infant Digestion Model
To prevent infectious diarrhea in infants, orally-supplemented enteric pathogen-specific recombinant antibodies would need to resist degradation in the gastrointestinal tract. Palivizumab, a recombinant antibody specific to respiratory syncytial virus (RSV), was used as a model to assess the digesti...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-02-01
|
Series: | Nutrients |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6643/12/3/621 |
id |
doaj-825b809cfc244846b1a112113df709f4 |
---|---|
record_format |
Article |
spelling |
doaj-825b809cfc244846b1a112113df709f42020-11-25T01:19:53ZengMDPI AGNutrients2072-66432020-02-0112362110.3390/nu12030621nu12030621Survival of Recombinant Monoclonal Antibodies (IgG, IgA and sIgA) Versus Naturally-Occurring Antibodies (IgG and sIgA/IgA) in an Ex Vivo Infant Digestion ModelJiraporn Lueangsakulthai0Baidya Nath P. Sah1Brian P. Scottoline2David C. Dallas3Nutrition Program, School of Biological and Population Health Sciences, College of Public Health and Human Sciences, Oregon State University, Corvallis, OR 97331, USANutrition Program, School of Biological and Population Health Sciences, College of Public Health and Human Sciences, Oregon State University, Corvallis, OR 97331, USADepartment of Pediatrics, Oregon Health and Sciences University, Portland, OR 97239, USANutrition Program, School of Biological and Population Health Sciences, College of Public Health and Human Sciences, Oregon State University, Corvallis, OR 97331, USATo prevent infectious diarrhea in infants, orally-supplemented enteric pathogen-specific recombinant antibodies would need to resist degradation in the gastrointestinal tract. Palivizumab, a recombinant antibody specific to respiratory syncytial virus (RSV), was used as a model to assess the digestion of neutralizing antibodies in infant digestion. The aim was to determine the remaining binding activity of RSV F protein-specific monoclonal and naturally-occurring immunoglobulins (Ig) in different isoforms (IgG, IgA, and sIgA) across an ex vivo model of infant digestion. RSV F protein-specific monoclonal immunoglobulins (IgG, IgA, and sIgA) and milk-derived naturally-occurring Ig (IgG and sIgA/IgA) were exposed to an ex vivo model of digestion using digestive samples from infants (gastric and intestinal samples). The survival of each antibody was tested via an RSV F protein-specific ELISA. Ex vivo gastric and intestinal digestion degraded palivizumab IgG, IgA, and sIgA (<i>p </i>< 0.05). However, the naturally-occurring RSV F protein-specific IgG and sIgA/IgA found in human milk were stable across gastric and intestinal ex vivo digestion. The structural differences between recombinant and naturally-occurring antibodies need to be closely examined to guide future design of recombinant antibodies with increased stability for use in the gastrointestinal tract.https://www.mdpi.com/2072-6643/12/3/621palivizumabimmunoglobulinsinfantsrespiratory syncytial virusgastrointestinal digestion |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Jiraporn Lueangsakulthai Baidya Nath P. Sah Brian P. Scottoline David C. Dallas |
spellingShingle |
Jiraporn Lueangsakulthai Baidya Nath P. Sah Brian P. Scottoline David C. Dallas Survival of Recombinant Monoclonal Antibodies (IgG, IgA and sIgA) Versus Naturally-Occurring Antibodies (IgG and sIgA/IgA) in an Ex Vivo Infant Digestion Model Nutrients palivizumab immunoglobulins infants respiratory syncytial virus gastrointestinal digestion |
author_facet |
Jiraporn Lueangsakulthai Baidya Nath P. Sah Brian P. Scottoline David C. Dallas |
author_sort |
Jiraporn Lueangsakulthai |
title |
Survival of Recombinant Monoclonal Antibodies (IgG, IgA and sIgA) Versus Naturally-Occurring Antibodies (IgG and sIgA/IgA) in an Ex Vivo Infant Digestion Model |
title_short |
Survival of Recombinant Monoclonal Antibodies (IgG, IgA and sIgA) Versus Naturally-Occurring Antibodies (IgG and sIgA/IgA) in an Ex Vivo Infant Digestion Model |
title_full |
Survival of Recombinant Monoclonal Antibodies (IgG, IgA and sIgA) Versus Naturally-Occurring Antibodies (IgG and sIgA/IgA) in an Ex Vivo Infant Digestion Model |
title_fullStr |
Survival of Recombinant Monoclonal Antibodies (IgG, IgA and sIgA) Versus Naturally-Occurring Antibodies (IgG and sIgA/IgA) in an Ex Vivo Infant Digestion Model |
title_full_unstemmed |
Survival of Recombinant Monoclonal Antibodies (IgG, IgA and sIgA) Versus Naturally-Occurring Antibodies (IgG and sIgA/IgA) in an Ex Vivo Infant Digestion Model |
title_sort |
survival of recombinant monoclonal antibodies (igg, iga and siga) versus naturally-occurring antibodies (igg and siga/iga) in an ex vivo infant digestion model |
publisher |
MDPI AG |
series |
Nutrients |
issn |
2072-6643 |
publishDate |
2020-02-01 |
description |
To prevent infectious diarrhea in infants, orally-supplemented enteric pathogen-specific recombinant antibodies would need to resist degradation in the gastrointestinal tract. Palivizumab, a recombinant antibody specific to respiratory syncytial virus (RSV), was used as a model to assess the digestion of neutralizing antibodies in infant digestion. The aim was to determine the remaining binding activity of RSV F protein-specific monoclonal and naturally-occurring immunoglobulins (Ig) in different isoforms (IgG, IgA, and sIgA) across an ex vivo model of infant digestion. RSV F protein-specific monoclonal immunoglobulins (IgG, IgA, and sIgA) and milk-derived naturally-occurring Ig (IgG and sIgA/IgA) were exposed to an ex vivo model of digestion using digestive samples from infants (gastric and intestinal samples). The survival of each antibody was tested via an RSV F protein-specific ELISA. Ex vivo gastric and intestinal digestion degraded palivizumab IgG, IgA, and sIgA (<i>p </i>< 0.05). However, the naturally-occurring RSV F protein-specific IgG and sIgA/IgA found in human milk were stable across gastric and intestinal ex vivo digestion. The structural differences between recombinant and naturally-occurring antibodies need to be closely examined to guide future design of recombinant antibodies with increased stability for use in the gastrointestinal tract. |
topic |
palivizumab immunoglobulins infants respiratory syncytial virus gastrointestinal digestion |
url |
https://www.mdpi.com/2072-6643/12/3/621 |
work_keys_str_mv |
AT jirapornlueangsakulthai survivalofrecombinantmonoclonalantibodiesiggigaandsigaversusnaturallyoccurringantibodiesiggandsigaigainanexvivoinfantdigestionmodel AT baidyanathpsah survivalofrecombinantmonoclonalantibodiesiggigaandsigaversusnaturallyoccurringantibodiesiggandsigaigainanexvivoinfantdigestionmodel AT brianpscottoline survivalofrecombinantmonoclonalantibodiesiggigaandsigaversusnaturallyoccurringantibodiesiggandsigaigainanexvivoinfantdigestionmodel AT davidcdallas survivalofrecombinantmonoclonalantibodiesiggigaandsigaversusnaturallyoccurringantibodiesiggandsigaigainanexvivoinfantdigestionmodel |
_version_ |
1725136667468103680 |